Towards the understanding of the activity of G9a inhibitors: an activity landscape and molecular modeling approach

In this work, we analyze the structure–activity relationships (SAR) of epigenetic inhibitors (lysine mimetics) against lysine methyltransferase (G9a or EHMT2) using a combined activity landscape, molecular docking and molecular dynamics approach. The study was based on a set of 251 G9a inhibitors wi...

Descripción completa

Detalles Bibliográficos
Autores: López‑López, E. (Edgar)|||/items/4b04b1c3-3f1a-4f71-aa82-9dc55ba658bb, Rabal, O. (Obdulia)|||/items/f58a6446-175d-45a0-9bed-83b4e61858c4, Oyarzabal, J. (Julen)|||/items/5fe770fd-2181-41c9-a467-28cc89a40250, Medina-Franco, J.L. (José L.)|||/items/7551f0b1-613f-4da3-bef2-5b114679ad3a
Tipo de recurso: artículo
Fecha de publicación:2020
País:España
Institución:Universidad de Navarra
Repositorio:Dadun. Depósito Académico Digital de la Universidad de Navarra
Idioma:inglés
OAI Identifier:oai:dadun.unav.edu:10171/67299
Acceso en línea:https://hdl.handle.net/10171/67299
Access Level:acceso abierto
Palabra clave:Activity clifs
Drug discovery
EHMT2
Epi-pharmacology
Scafold hops
Structure–activity relationships
Descripción
Sumario:In this work, we analyze the structure–activity relationships (SAR) of epigenetic inhibitors (lysine mimetics) against lysine methyltransferase (G9a or EHMT2) using a combined activity landscape, molecular docking and molecular dynamics approach. The study was based on a set of 251 G9a inhibitors with reported experimental activity. The activity landscape analysis rapidly led to the identifcation of activity clifs, scafolds hops and other active an inactive molecules with distinct SAR. Structure-based analysis of activity clifs, scafold hops and other selected active and inactive G9a inhibitors by means of docking followed by molecular dynamics simulations led to the identifcation of interactions with key residues involved in activity against G9a, for instance with ASP 1083, LEU 1086, ASP 1088, TYR 1154 and PHE 1158. The outcome of this work is expected to further advance the development of G9a inhibitors.